Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial

Table 3 Primary Outcome and Bleeding Events

Characteristic	All Randomized (N = 533)	Minimal Contact enrollment (N = 306)	Acute Episodic Care enrollment (N = 227)	p-value^#
Adjudicated primary outcomes—no. (%)
Composite primary endpoint	20 (3.8)	2 (0.7)	18 (7.9)	< 0.001
Cardio-pulmonary hospitalizations	20 (3.8)	2 (0.7)	18 (7.9)	< 0.001
COVID-19 associated pneumonia	20 (3.8)	2 (0.7)	18 (7.9)	< 0.001
Deep vein thrombosis or pulmonary embolism	1 (0.2)	0 (0.0)	1 (0.4)	0.43
Myocardial infarction, stroke or other arterial embolism	0 (0.0)	0 (0.0)	0 (0.0)	-
Death	1 (0.2)	0 (0.0)	1 (0.4)	0.43
Suspected Hemorrhagic Events—no. (%)*
Major bleeding	0 (0.0)	0 (0.0)	0 (0.0)	-
Clinically relevant non-major bleeding	13 (2.4)	6 (2.0)	7 (3.1)	0.41
Minor bleeding	17 (3.2)	8 (2.6)	9 (4.0)	0.46
Adjudicated Hemorrhagic Events—no. (%)
Major bleeding	0 (0.0)	0 (0.0)	0 (0.0)	-
Clinically relevant non-major bleeding	5 (0.9)	2 (0.7)	3 (1.3)	0.66

*Suspected major and clinically relevant non-major bleeding events were reported by the trial medical monitor, and minor bleeding events were identified through follow-up with the research pharmacists. Major and clinically relevant non-major bleeding events were adjudicated by the Clinical Events Committee; minor bleeding events were not adjudicated.
# p-values comparing outcome risk in the Minimal Contact enrollment to that in the Acute Episodic Care enrollment group are based on Fisher’s exact tests.

ISSN: 1471-2334